January 28, 2019
Theravance Biopharma doses nOH patients in Phase 3 testing investigational inhibitor ampreloxetine
Theravance Biopharma has started dosing patients with symptomatic neurogenic orthostatic hypotension (nOH) to test its investigational neropinephrine reuptake inhibitor ampreloxetine (TD-9855), in a registrational Phase 3 clinical trial